DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER-Reference-Cited by-同舟云学术

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

Published:2000-03 Issue:3 Volume:163 Page:834-837
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

WEITZMAN AARON L.¹,SHELTON GARY¹,ZUECH NANCY¹,OWEN CINDY ENGLAND¹,JUDGE TIMOTHY¹,BENSON MITCHELL¹,SAWCZUK IHOR¹,KATZ AARON¹,OLSSON CARL A.¹,BAGIELLA EMILIA¹,PFAFF CHARLES¹,NEWHOUSE JEFFREY H.¹,PETRYLAK DANIEL P.¹

Affiliation:

1. From the Departments of Medicine, Urology, Radiology and Biostatistics, Division of Medical Oncology, Columbia Presbyterian Medical Center, New York, New York

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference28 articles.

1. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines;Kreis;Br J Uro,1997

2. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines;Speicher;Cancer Res,1992

3. Phase I/II studies of the combination of estramustine and docetaxel in hormone-refractory prostate cancer;Petrylak;Semin Oncol,1999

4. Estramustine depolymerizes microtubules by binding to tubulin;Dahllof;Cancer Res,1993

5. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells;Stearns;J Cell Biol,1988

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of short‐term dexamethasone on the efficacy of 177 Lu‐PSMA‐617 in patients with metastatic castration‐resistant prostate cancer;The Prostate;2020-03-18

2. PSA response following the ‘steroid switch’ in patients with castration‑resistant prostate cancer treated with abiraterone: A case report;Oncology Letters;2018-08-17

3. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis;International Journal of Surgery;2018-08

4. Corticosteroid Therapy for CRPC;Hormone Therapy and Castration Resistance of Prostate Cancer;2018

5. Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy;Nature Reviews Urology;2015-12-08